Pharmaceuticals company RPG Life Sciences announced Q2FY24 & H1FY24 results: Financial Performance: - Revenue from operations for Q2FY24 grew by 14% YoY and 4% QoQ, reaching Rs 153.58 crore. - Revenue from operations for H1FY24 grew by 14% YoY, reaching Rs 301.36 crore. - PBT (Profit Before Tax) for Q2FY24 grew by 29% YoY and 17% QoQ. - PBT for H1FY24 grew by 29% YoY. - EBITDA margins improved from 23.0% to 25.5% YoY and QoQ. - The company remained debt-free during this period. Domestic Formulations Business: - The domestic formulations business, the largest contributor to the company's revenue, performed strongly. - The business recorded robust growth in value and volume, surpassing the market growth consistently. - Legacy brands, supported by a comprehensive life cycle management program, achieved healthy growth and became bigger brands. - The new product portfolio in newer and progressive segments is shaping new therapies and expanding the company's product offerings. - Foray into Rheumatology strengthened the company's Specialty segment. - MABs portfolio posted robust performance. - Salesforce productivity continued to register healthy upward momentum. International Formulations Business: - The international formulations business showed robust growth, emerging as another growth driver for the company. - The business registered substantial growth in both sales and profits. API Business: - The API (Active Pharmaceutical Ingredients) business recorded healthy growth and margin improvement. Future Plans and Initiatives: - The company is investing in plant modernization and capacity expansion for both formulations and API. - Focus is on building a healthy product pipeline to accelerate exports. - Cost efficiencies in operations and sales hygiene are consistently improving margins. - Implementation of the Transformation Agenda is on track to achieve strategic goals. Yugal Sikri, Managing Director, RPG Life Sciences, said, “In Q2FY24, the overall performance of the Company continued to be strong. Revenue and PBT grew by 14% and 29% respectively YoY. EBITDA margin retained its 5-year long upward trajectory growing from 23.0% to 25.5% YoY. The Company continues to remain debt-free. Domestic Formulations business, the biggest contributor to the Company's business, recorded robust growth both in value and volume - significantly and consistently ahead of the market. While our comprehensive life cycle management program for legacy brands is helping them register healthy growth and become bigger brands, our new product portfolio comprising of newer and progressive segments is also shaping new therapies and product portfolio. Our foray into Rheumatology has strengthened our Specialty segment. Our MABs portfolio is continuing to post robust performance. Salesforce productivity continues to register healthy upward momentum. International Formulations business has also shown robust growth while emerging as another growth driver for the Company, registering healthy growth in both sales and profits. API business also registered healthy growth and improvement in margin. The Company is investing in plant modernization and capacity expansion in both plants as well as working on building a healthy product pipeline to accelerate exports of both formulations and API. Our relentless focus on achieving cost efficiencies in our operations, and eye on sales hygiene, is helping us to consistently improve our margins. We are well on course to implement our Transformation Agenda to achieve our strategic goals." Result PDF
Pharmaceuticals company RPG Life Sciences announced Q4FY23 & FY23 results: Q4FY23: PBT up by 26% YoY for Q4FY23, maintaining the upward trajectory in EBITDA margins, which improved from 14.2% to 15.0% YoY Revenue from operations at Rs 118.49 crore registered a growth of 14% YoY for Q4FY23 FY23: For FY23, the company posted a jump in PBT by 25% YoY and recorded EBITDA margin expansion from 20.3% to 21.0% YoY Revenue from operations at Rs 512.81 crore registered a growth of 17% YoY for FY23 Yugal Sikri, Managing Director, RPG Life Sciences said, “In Q4 FY23, the company maintained its upward trajectory of overall robust performance by posting yet another strong result despite the ongoing geo-political challenges impacting supply chain and costs. Revenue and PBT grew by a healthy 14% and 26% respectively YoY. EBITDA margins’ consistent upward trajectory has continued for the last 5 years, growing from 10.4% (FY19) to 15.9%(FY20) to 18.2% (FY21) to 20.3% (FY22) to 21.0% (FY23). The company continues to remain debt-free with the highest-ever net cashflow generated from operations in full-year FY23. Its domestic formulations business, the biggest contributor to the company’s business, recorded robust growth both in value and volume - significantly and consistently ahead of the market. While our comprehensive life cycle management program for legacy brands is helping them register healthy growth, our new product portfolio comprising newer and progressive segments is also witnessing an impressive uptake. Our foray into Rheumatology has strengthened our Specialty segment. Our MABs portfolio is continuing to post robust performance. Our digitalization initiatives are showing strong traction. Salesforce productivity continues to register healthy upward momentum across business segments. International Formulations business has also shown robust growth, while emerging as another growth driver for the company, registering healthy growth in both sales and profits. The company is investing in plant upgradation and capacity expansion in both plants as well as working on building a healthy product pipeline to accelerate exports. Our relentless focus on achieving cost efficiencies in our operations, and eye on sales hygiene, are helping us to improve our margins consistently. We are well on course to implement our transformation agenda to achieve our strategic goals.” Result PDF
Pharmaceuticals firm RPG Life Sciences announced Q3FY23 results: Q3FY23 & 9MFY23: RPG Life Sciences posted a jump in PBT by 25% YoY for Q3FY23, maintaining the upward trajectory in EBITDA margins, which improved from 21.4% to 22.8% YoY. Revenue from operations at Rs 130.60 crores registered a growth of 13% YoY for Q3FY23. For 9MFY23 too, the company posted a jump in PBT by 25% YoY and recorded EBITDA margin expansion from 22.2% to 22.8% YoY. Revenue from operations at Rs 394.32 crores registered a growth of 17% YoY for 9MFY23. Mr. Yugal Sikri, Managing Director, RPG Life Sciences Ltd. said, “In Q3 FY23, Company maintained its upward trajectory of overall robust performance by posting yet another strong results despite the ongoing geo-political challenges impacting supply chain and costs. Revenue and PBT grew by healthy 13% and 25% respectively YoY. EBITDA margin grew from 21.4% to 22.8% YoY. Domestic Formulations business, the biggest contributor to company business, recorded robust growth both in value and volumes - significantly and consistently ahead of the market. While our comprehensive life cycle management program for legacy brands is helping them register healthy growth, our new product portfolio comprising of newer and progressive segments is also witnessing an impressive uptake. Our foray into Rheumatology has strengthened our Specialty segment. Our MABs portfolio is continuing to post robust performance. Our digitalization initiatives are showing strong traction. Salesforce productivity continues to register healthy upward momentum across business segments. International Formulations business has also shown robust growth while API business has also picked up growth momentum. Our relentless focus on achieving cost efficiencies in our operations, eye on sales hygiene, is helping us to consistently improve our margins. We are well on course to implement our Transformation Agenda to achieve our strategic goals.” Result PDF
Conference Call with RPG Life Sciences Management and Analysts on Q2FY23 Performance and Outlook. Listen to the full earnings transcript.